REYVOWE Trademark

Trademark Overview


On Thursday, May 11, 2017, a trademark application was filed for REYVOWE with the United States Patent and Trademark Office. The USPTO has given the REYVOWE trademark a serial number of 87446491. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, December 21, 2020. This trademark is owned by Eli Lilly and Company. The REYVOWE trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, gastrointestinal diseases and disorders, hypoglycemia, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, mental disorders, metabolic diseases and disorders, migraines, multiple sclerosis, muscle diseases and disorders, neurodegenerative diseases and disorders, neurological disorders, pain, Parkinson's disease, Psoriatic arthritis, rheumatoid arthritis, Sjogren's syndrome, sleep disorders, spondyloarthropathy, systemic lupus erythematosus, ulcerative colitis; Diagnostic agents ...
reyvowe

General Information


Serial Number87446491
Word MarkREYVOWE
Filing DateThursday, May 11, 2017
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, December 21, 2020
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, September 19, 2017

Trademark Statements


Goods and ServicesPharmaceutical preparations, namely, pharmaceutical preparations for the treatment of Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, gastrointestinal diseases and disorders, hypoglycemia, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, mental disorders, metabolic diseases and disorders, migraines, multiple sclerosis, muscle diseases and disorders, neurodegenerative diseases and disorders, neurological disorders, pain, Parkinson's disease, Psoriatic arthritis, rheumatoid arthritis, Sjogren's syndrome, sleep disorders, spondyloarthropathy, systemic lupus erythematosus, ulcerative colitis; Diagnostic agents and substances for medical purposes; radiopharmaceutical diagnostic preparations for use in the diagnosis of neurodegenerative diseases

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, May 16, 2017
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameEli Lilly and Company
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressIndianapolis, IN 46285

Party NameEli Lilly and Company
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressIndianapolis, IN 46285

Trademark Events


Event DateEvent Description
Monday, December 21, 2020ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, December 21, 2020ABANDONMENT - NO USE STATEMENT FILED
Tuesday, April 21, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, April 20, 2020EXTENSION 5 GRANTED
Thursday, April 16, 2020EXTENSION 5 FILED
Thursday, April 16, 2020TEAS EXTENSION RECEIVED
Wednesday, October 16, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, October 14, 2019EXTENSION 4 GRANTED
Monday, October 14, 2019EXTENSION 4 FILED
Monday, October 14, 2019TEAS EXTENSION RECEIVED
Wednesday, April 10, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, April 8, 2019EXTENSION 3 GRANTED
Monday, April 8, 2019EXTENSION 3 FILED
Monday, April 8, 2019TEAS EXTENSION RECEIVED
Friday, October 19, 2018NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, October 17, 2018EXTENSION 2 GRANTED
Wednesday, October 17, 2018EXTENSION 2 FILED
Wednesday, October 17, 2018TEAS EXTENSION RECEIVED
Thursday, May 17, 2018NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, May 16, 2018EXTENSION 1 GRANTED
Tuesday, May 1, 2018EXTENSION 1 FILED
Wednesday, May 16, 2018CASE ASSIGNED TO INTENT TO USE PARALEGAL
Tuesday, May 1, 2018TEAS EXTENSION RECEIVED
Tuesday, November 14, 2017NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, September 19, 2017OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, September 19, 2017PUBLISHED FOR OPPOSITION
Wednesday, August 30, 2017NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Friday, August 11, 2017APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, August 9, 2017ASSIGNED TO EXAMINER
Tuesday, May 16, 2017NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Monday, May 15, 2017NEW APPLICATION ENTERED IN TRAM